F-18 Fluorodeoxyglucose PET/CT as a Diagnostic Tool in Orbital Inflammatory Disorders. (17th November 2022)

• Record Type: Journal Article
• Authors: Elourimi, Ghassan; Soussan, Michael; Groh, Matthieu; Martin, Antoine; Héran, Francoise; Galatoire, Olivier; Dhote, Robin; Vicaut, Eric; Abad, Sébastien
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 7/8(2022)
• Page Start: 1803
• Page End: 1809
• Publication Date: 2022-11-17
• Subjects: Adnexal orbital lymphoma -- FDG-PET/CT -- idiopathic orbital inflammatory syndrome -- IgG4-related ophthalmic disease -- inflammatory orbital pseudotumor; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1957943
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To assess the usefulness of FDG-PET/CT as a potential diagnostic tool for detecting underlying systemic diseases (SD) in patients with orbital inflammatory disorders (OID). Methods: All consecutive patients managed for new-onset OID between 2011 and 2018 in a tertiary referral center, who underwent FDG-PET/CT as part of the etiological diagnostic workup were evaluated. To quantify the incremental value of FDG-PET/CT over standard diagnostic workup, the Net Reclassification Index (NRI) and Integrated Discrimination Index (IDI) were used. Results: Among the 22 patients enrolled, 11 (50%) had a positive FDG-PET/CT. After clinicobiological evaluation, FDG-PET/CT correctly reclassified 4(29%) of 14 patients with SD ( p = .04) and 1(13%) of 8 with idiopathic orbital inflammation syndrome ( p = .32). NRI and IDI were 0.41 ± 0.17 ( p = .03) and 0.38 ± 0.08 ( p < .001), respectively. FDG-PET/CT successfully detected asymptomatic lesions in all (n = 4) patients with lymphoma. Conclusion: FDG-PET/CT enabled accurate reclassification of more than one-quarter of patients with SD, especially extraorbital lymphomas.